Figure 1.

Experimental protocol for sensitization with OVA and treatment with a lentivirus-mediated sponge for miR-205-5p. The AR mice were sensitized via an intraperitoneal injection of saline containing 25 µg OVA and 2 mg aluminum hydroxide on days 0, 7 and 14. The mice were then subjected to continuous intranasal challenges with 100 µg OVA (50 µl; 2 mg/ml) on days 21–27. The sham group was administered an equivalent amount of saline without OVA or aluminum hydroxide on days 0, 7 and 14, and on days 21–27. A total of 24 h before each OVA challenge on days 21–27, a recombinant lentiviral vector carrying a anti-miR-205-5p sponge or NC (20 µl; 1×10⁸ TU/ml) was intranasally administered to the mice in the AR + NC and AR + Lv-anti-miR-205-5p sponge groups, respectively. AR, allergic rhinitis; miR, microRNA; NC, negative control; OVA, ovalbumin.